VRCA - Verrica Pharmaceuticals - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

180.9M

Cash

59.95M

Avg Qtr Burn

-3.725M

Short % of Float

8.64%

Insider Ownership

39.94%

Institutional Own.

23.74%

Qtr Updated

03/31/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
VP-102 (GMP-controlled formulation of cantharidin), YCANTH™ Details Infectious disease, Molluscum contagiosum Big Mover™ Suspected Mover™ Susp. Mover™	PDUFA Approval decision	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VP-102 (GMP-controlled formulation of cantharidin) Details Human papillomavirus, Genital Warts	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VP-315 Details Basal cell carcinoma	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VP-102 (GMP-controlled formulation of cantharidin) Details Human papillomavirus, Common Warts	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.